{"id":"lipotecan","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01425996","NCT00747474","NCT02457273","NCT02267213","NCT01831973","NCT03035006"],"aliases":["TLC388","Lipotecan, TLC388","Lipotecan (TLC388)"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Lipotecan","companyId":"taiwan-liposome-company","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Taiwan Liposome Company","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Lipotecan","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01425996","phase":"Phase 1","title":"A Phase I/II, Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Taiwan Liposome Company","isPivotal":false,"enrollment":3,"indication":"Carcinoma, Hepatocellular","completionDate":"2014-10-03"},{"nctId":"NCT00747474","phase":"Phase 1","title":"A Phase 1 Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) When Administered to Patients W","status":"COMPLETED","sponsor":"Taiwan Liposome Company","isPivotal":false,"enrollment":54,"indication":"Advanced Solid Tumors","completionDate":"2011-12"},{"nctId":"NCT02457273","phase":"Phase 2","title":"An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Poorly Differentiated Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","isPivotal":false,"enrollment":23,"indication":"Neuroendocrine Carcinomas","completionDate":"2018-12-01"},{"nctId":"NCT02267213","phase":"Phase 2","title":"An Open-Label, Single-Arm, Two-Stage, Multi-Centre Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Taiwan Liposome Company","isPivotal":false,"enrollment":29,"indication":"Hepatocellular Carcinoma","completionDate":"2015-07-09"},{"nctId":"NCT01831973","phase":"Phase 2","title":"An Open-Label, Single-Arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Patients With Advanced/Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Taiwan Liposome Company","isPivotal":false,"enrollment":18,"indication":"Advanced/Metastasis Renal Cell Carcinoma","completionDate":"2017-02-21"},{"nctId":"NCT03035006","phase":"Phase 1","title":"A Phase I/II, Dose-escalation Study of Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis","status":"TERMINATED","sponsor":"Taiwan Liposome Company","isPivotal":false,"enrollment":1,"indication":"HepatoCellular Carcinoma, Portal Vein Tumor Thrombosis","completionDate":"2018-10-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}